Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.12
- Piotroski Score 2.00
- Grade Underweight
- Symbol (AVIR)
- Company Atea Pharmaceuticals, Inc.
- Price $3.35
- Changes Percentage (-2.62%)
- Change -$0.09
- Day Low $3.34
- Day High $3.48
- Year High $4.60
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.88
- High Stock Price Target $6.88
- Low Stock Price Target $6.88
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.95
- Trailing P/E Ratio -1.9
- Forward P/E Ratio -1.9
- P/E Growth -1.9
- Net Income $-135,956,000
Income Statement
Quarterly
Annual
Latest News of AVIR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Jason Kelce Reveals Why He Couldn't Turn Down the Chance to Arm Wrestle Team USA's Nicole Heavirland
Jason Kelce reflects on his experience at the 2024 Paris Olympics, where he engaged in a viral arm wrestling match with Team USA rugby star Nicole Heavirland. Despite initial hesitation, Kelce embrace...
By PEOPLE.com | 1 month ago -
Jason Kelce Arm Wrestles with Team USA Rugby Star Nicole Heavirland as Wife Kylie Calls Him Out for Cheating
Former Philadelphia Eagles center, Jason Kelce, beat Team USA women's rugby star Nicole Heavirland in an arm wrestling challenge. Despite the win, there were suggestions of rule-breaking. Kelce was de...
By PEOPLE.com | 2 months ago -
NIH-funded trial finds HIV drug abacavir linked to higher cardiovascular risk
NIH-funded REPRIEVE trial finds that HIV drug abacavir is associated with a higher risk of cardiovascular events. A daily statin regimen was shown to reduce MACE risk by over one-third. Further resear...
By Yahoo! Finance | 2 months ago
